Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 3/20 | 0.43 |
| ▸ | POLA1 | P09884 | 2/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6418754 | 0.90 | KCNH2 (0.53) | KCNH2POLA1 | |
| SCHEMBL6413701 | 0.90 | POLA1 (0.43) | KCNH2POLA1TSHR | |
| SCHEMBL6414980 | 0.87 | POLA1 (0.40) | KCNH2POLA1 | |
| SCHEMBL6413905 | 0.85 | POLA1 (0.57) | KCNH2POLA1TSHR | |
| SCHEMBL6412414 | 0.85 | POLA1 (0.40) | KCNH2POLA1TSHR | |
| SCHEMBL6698303 | 0.82 | KCNH2 (0.38) | KCNH2POLA1 | |
| SCHEMBL6415572 | 0.81 | POLA1 (0.53) | KCNH2POLA1 | |
| SCHEMBL6412912 | 0.78 | POLA1 (0.49) | KCNH2POLA1 | |
| SCHEMBL6412903 | 0.77 | POLA1 (0.38) | KCNH2POLA1TSHR | |
| SCHEMBL6419447 | 0.76 | POLA1 (0.69) | KCNH2POLA1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1359917-B1 | THIOXAZINOQUINOLONES USEFUL FOR THE TREATMENT OF VIRAL INFECTIONS | PHARMACIA & UPJOHN CO LLC (US) | 2005-06-29 | — | — | EP | claimed |
| US-6821969-B2 | FOR THERAPY AND PROPHYLAXIS OF HERPESVIRAL INFECTION | PHARMACIA & UPJOHN COMPANY | 2004-11-23 | — | — | US | claimed |
| EP-1359917-A1 | THIOXAZINOQUINOLONES USEFUL FOR THE TREATMENT OF VIRAL INFECTIONS | PHARMACIA & UPJOHN COMPANY (US) | 2003-11-12 | — | — | EP | claimed |
| US-20020143013-A1 | Thioxazinoquinolones as antiviral agents | PHARMACIA & UPJOHN COMPANY | 2002-10-03 | — | — | US | claimed |
| WO-2002064145-A1 | THIOXAZINOQUINOLONES USEFUL FOR THE TREATMENT OF VIRAL INFECTIONS | PHARMACIA & UPJOHN COMPANY (US) | 2002-08-22 | — | — | WO | claimed |
| EP-1359917-B1 | THIOXAZINOQUINOLONES USEFUL FOR THE TREATMENT OF VIRAL INFECTIONS | PHARMACIA & UPJOHN CO LLC (US) | 2005-06-29 | — | — | EP | disclosed |
| US-6821969-B2 | FOR THERAPY AND PROPHYLAXIS OF HERPESVIRAL INFECTION | PHARMACIA & UPJOHN COMPANY | 2004-11-23 | — | — | US | disclosed |
| EP-1359917-A1 | THIOXAZINOQUINOLONES USEFUL FOR THE TREATMENT OF VIRAL INFECTIONS | PHARMACIA & UPJOHN COMPANY (US) | 2003-11-12 | — | — | EP | disclosed |
| US-20020143013-A1 | Thioxazinoquinolones as antiviral agents | PHARMACIA & UPJOHN COMPANY | 2002-10-03 | — | — | US | disclosed |
| WO-2002064145-A1 | THIOXAZINOQUINOLONES USEFUL FOR THE TREATMENT OF VIRAL INFECTIONS | PHARMACIA & UPJOHN COMPANY (US) | 2002-08-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020143013-A1 | Thioxazinoquinolones as antiviral agents | DDX5, IRF3, ZC3HAV1 | KCNH2 960/4885POLA1 135/4885TSHR 3123/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.